Literature DB >> 1267432

Rosamicin: in vitro activity against anaerobes and comparison with erythromycin.

V L Sutter, S M Finegold.   

Abstract

The in vitro activity of rosamicin was determined against 231 strains of anaerobic bacteria and compared with the activity of erythromycin against the same strains. Rosamicin and erythromycin had similar activity against strains of Peptostreptococcus and gram-positive nonsporeforming bacilli. Rosamicin was somewhat more active against strains of Peptococcus, Clostridium, and gram-negative anaerobes. All strains of Bacteroides fragilis tested were inhibited by 4 mug of rosamicin or less per ml, whereas only 76% of them were inhibited by this concentration of erythromycin. Rosamicin was distinctly more active against Fusobacterium nucleatum. Because of its in vitro activity, further investigation of the pharmacology of this drug is warranted.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 1267432      PMCID: PMC429526          DOI: 10.1128/AAC.9.2.350

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  3 in total

1.  Biological studies with rosamicin, a new Micromonospora-produced macrolide antibiotic.

Authors:  J A Waitz; C G Drube; E L Moss; M J Weinstein
Journal:  J Antibiot (Tokyo)       Date:  1972-11       Impact factor: 2.649

2.  Rosamicin: evaluation in vitro and comparison with erythromycin and lincomycin.

Authors:  C C Crowe; W E Sanders
Journal:  Antimicrob Agents Chemother       Date:  1974-03       Impact factor: 5.191

3.  A new Micromonospora-produced macrolide antibiotic, rosamicin.

Authors:  G H Wagman; J A Waitz; J Marquez; A Murawaski; E M Oden; R T Testa; M J Weinstein
Journal:  J Antibiot (Tokyo)       Date:  1972-11       Impact factor: 2.649

  3 in total
  11 in total

1.  Susceptibility of skin and throat strains of group A streptococci to rosamicin and erythromycin.

Authors:  G Saroglou; A L Bisno
Journal:  Antimicrob Agents Chemother       Date:  1978-04       Impact factor: 5.191

2.  Pharmacokinetics and metabolism of rosaramicin in humans.

Authors:  C C Lin; M Chung; R Gural; D Schuessler; H K Kim; E Radwanski; A Marco; C DiGiore; S Symchowicz
Journal:  Antimicrob Agents Chemother       Date:  1984-10       Impact factor: 5.191

3.  In vitro activity of rosamicin and erythromycin against a group of nonfermenting gram-negative bacilli.

Authors:  J R DiPersio; T L Krafczyk
Journal:  Antimicrob Agents Chemother       Date:  1978-08       Impact factor: 5.191

4.  In vitro susceptibility of 30 strains of Chlamydia trachomatis to rosamicin.

Authors:  T F Smith; H E Washton
Journal:  Antimicrob Agents Chemother       Date:  1978-09       Impact factor: 5.191

5.  Josamycin and rosamicin: in vitro comparisons with erythromycin and clindamycin.

Authors:  S Shadomy; M Tipple; L Paxton
Journal:  Antimicrob Agents Chemother       Date:  1976-10       Impact factor: 5.191

6.  In vitro activity of josamycin and rosamicin against Bacteroides fragilis compared with clindamycin, erythromycin, and metronidazole.

Authors:  J Santoro; D Kaye; M E Levison
Journal:  Antimicrob Agents Chemother       Date:  1976-07       Impact factor: 5.191

7.  Susceptibility of anaerobic bacteria to 23 antimicrobial agents.

Authors:  V L Sutter; S M Finegold
Journal:  Antimicrob Agents Chemother       Date:  1976-10       Impact factor: 5.191

8.  In vitro activity of rosamicin against Neisseria and Haemophilus, including penicillinase-producing strains.

Authors:  C C Sanders; W E Sanders
Journal:  Antimicrob Agents Chemother       Date:  1977-08       Impact factor: 5.191

9.  Rosamicin--a new drug for the treatment of bacterial prostatitis.

Authors:  A Baumueller; U Hoyme; P O Madsen
Journal:  Antimicrob Agents Chemother       Date:  1977-08       Impact factor: 5.191

10.  Medium for selective isolation of Fusobacterium nucleatum from human periodontal pockets.

Authors:  C B Walker; D Ratliff; D Muller; R Mandell; S S Socransky
Journal:  J Clin Microbiol       Date:  1979-12       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.